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(ie, Flow2CAST), although we are aware of its lim-
itations. There is no doubt that the BAT can pro-
vide a valuable complementary tool in the diag-
nosis of allergy and in patient selection for SIT. 
It is likely that in order to further refine treat-
ment choice and, consequently, its effectiveness, it 
will be necessary to combine the BAT with oth-
er tools in the panels of biomarkers.3 For techni-cal 
reasons, research on the BAT is conducted on 
groups of a few dozen patients, so it is necessary 
to repeat similar experiments in larger popula-
tions and using optimized protocols.
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Authors’ reply We are grateful to Dr. Chirum-
bolo for the comment on our paper describing 
the correlation between a nasal provocation test 
(NPT) and a basophil activation test (BAT) in pa-
tients with allergic rhinitis (AR).1 We agree with 
most of the issues raised by Dr. Chirumbolo, but 
some points need to be addressed. Differentiation of 
AR, nonallergic AR (NAR), and local AR (LAR) 
requires further studies, and the use of the atop-ic 
patch test seems to be an interesting comple-ment 
to diagnostic workup, but only in the case of 
the reaction occurring in type IV hypersensitivity.2 
Our paper is part of a larger project encom-
passing studies on the usefulness of the BAT in 
type I hypersensitivity reactions, which have been 
conducted for several years by our research team, 
especially in patient selection for and monitor-
ing of specific immunotherapy (SIT). As noted by 
Heffler,3 the need for biomarkers assessing 
the probability of response to SIT before it is ini-
tiated, as well as biomarkers predicting the safety, 
long -term efficacy, and time to symptom relapse 
when SIT is stopped, is crucial and is still a hot 
topic in allergy and clinical immunology research.3 
Our study1 focuses on the possibility of replac-ing 
the NPT by BAT during patient selection for 
SIT.1,4,5 We knew the paper by Gomez et al6 and 
cited it in our paper. Owing to different aims, we 
used other inclusion criteria: our patients had 
a suspicion of AR based on history and the results of 
SPT or the measurement of serum immuno-
globulin E (sIgE) levels, and caused by an allergy to 
birch or house dust mites. In the second step, all 
patients underwent the NPT and BAT at the same 
time, with 2 allergens successively: birch and house 
dust mites. Gomez et al,5 referred patients for AR, 
NAR, LAR, and healthy controls on the basis of 
medical history and SPT, sIgE, and NPT results at 
baseline. In the second step, they per-formed only 
the BAT.6 
As rightly pointed out by Dr. Chirumbolo, we 
applied a different method of performing the BAT 
